Zhou Wei, Yang Wanli, Ma Jiaojiao, Zhang Hongwei, Li Zeng, Zhang Lei, Liu Jinqiang, Han Zhenyu, Wang Hu, Hong Liu
Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.
Department of General Surgery, NO.406 Hospital, Dalian 116041, Liaoning Province, China.
J Cancer. 2018 Jan 1;9(2):407-414. doi: 10.7150/jca.21394. eCollection 2018.
Digestive tract cancers (DTCs) is the most common malignant tumors in the world. Despite surgery and medical technology have witnessed the increasing development and sharp advancement in the past decade, DTCs remain a critical concern with high morbidity and mortality. Since a class of small noncoding RNAs termed miRNAs were identified several years ago, increasing studies have attempted to illustrate the relationship between the specific miRNAs dysregulated expression levels and the diseases phenotypic changes. For example, microRNA-483 (miR-483) aberrant expression plays a pivotal part in tumor biology in a variety of human cancer, including DTCs. In this review, we focus on the present key findings from recent profiling studies, discuss the use of miR-483 as a novel biomarker for DTCs. At the same time, we emphasize the significant diversities and technical difficulties must be overcome before clinically relevant signatures arose. It is believed that this might provide researchers an insight into the molecular targeting cancer treatment.
消化道癌（DTCs）是世界上最常见的恶性肿瘤。尽管在过去十年中，手术和医学技术有了不断发展和显著进步，但DTCs仍然是一个高发病率和高死亡率的关键问题。自从几年前一类称为miRNAs的小非编码RNA被发现以来，越来越多的研究试图阐明特定miRNAs表达水平失调与疾病表型变化之间的关系。例如，微小RNA-483（miR-483）的异常表达在包括DTCs在内的多种人类癌症的肿瘤生物学中起着关键作用。在这篇综述中，我们关注近期分析研究的当前关键发现，讨论将miR-483用作DTCs新型生物标志物的情况。同时，我们强调在出现临床相关特征之前必须克服的显著差异和技术难题。相信这可能为研究人员提供对分子靶向癌症治疗的深入了解。
